HK Stock Market Move | INSILICO (03696) surged more than 7% in early trading. The company's revenue has increased significantly in the first half of the year, turning losses into profits. Several strategic partnerships have already been reached this month.

INSILICO (03696) rose more than 7% in the morning session, rising 7.59% by the time of publication to HK$47.6, with a trading volume of HK$185 million. On the news front, INSILICO previously announced a profit, expecting first-half revenue to reach $102.5 million to $106.5 million, an increase of about 272.7% to 287.3% year-on-year; net profit of $33.5 million to $39.5 million, compared to a net loss of $19.2 million in the same period last year, achieving a turnaround from loss to profit; adjusted non-IFRS net profit of $45.5 million to $51.5 million. The intensive implementation of BD cooperation is the core driver of the company's high performance growth. It is worth noting that the company has reached multiple cooperation agreements in July. INSILICO has entered into another AI-driven drug discovery cooperation with CMS in the central nervous system field; INSILICO has also formed a strategic cooperation alliance with Bory Pharmaceutical Co., Ltd.; in addition, Tencent Health has formed a strategic cooperation with INSILICO, and the two sides will integrate the entire chain from basic computing power, large model base to biological molecule reasoning, accelerate the innovation drug development process, and promote the digitalization and efficiency improvement of the pharmaceutical industry.